Investigation of novel chemical inhibitors of human lysosomal acid lipase: Virtual screening and molecular docking studies

Combinatorial Chemistry and High Throughput Screening

Volumn 17, Issue 5, 2014, Pages 473-782

  Azam, Syed Sikander ^a   Abbasi, Sumra Wajid ^a   Tahir, Shifa ^a  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

Homology modelling; Lysosomal acid lipase; Molecular docking; Protein ligand interaction; Virtual screening

Indexed keywords

6[3 (BENZO[D][1,3]DIOXOL 5 YL) 1,2,4 OXADIAZOL 5 YL) 6,7 DIHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 5(4H) YL](4 FLUROPHENYL)METHANONE; AMINO ACID; AURINTRICARBOXYLIC ACID; CARBAMIC ACID DERIVATIVE; CHOLESTEROL; ESTERASE INHIBITOR; LYSOSOMAL ACID LIPASE INHIBITOR; TETRAHYDROLIPSTATIN; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; CHOLESTEROL ESTERASE; ENZYME INHIBITOR; LIPA PROTEIN, HUMAN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL PARAMETERS; CHEMICAL STRUCTURE; CHOLESTEROL HOMEOSTASIS; DOG; DRUG IDENTIFICATION; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HOMEOSTASIS; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STRUCTURE ANALYSIS; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DATABASE; DRUG DESIGN; METABOLISM; MOLECULAR GENETICS; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; DATABASES, PHARMACEUTICAL; DOGS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; SEQUENCE ALIGNMENT; STEROL ESTERASE;

EID: 84903727352     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/1386207317666140314093403     Document Type: Article

References (48)

1. Assmann, G.; Seedorf, U. In: The Metabolic and Molecular Bases of Inherited Disease Scriver CR, Beaudet AL, Sly WS, Valle D, Eds., McGraw Hill: New York, 1995, pp. 2563-2587.
2. Brown, M. S.; Goldstein, J. L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res., 1980, 21, 505-517
3. Wang, X.; Sato, R.; Brown, M.S.; Hua, X.; Goldstein, J.L. SREBP-1, a membrane bound transcription factor released by sterolregulated proteolysis. Cell, 1994, 77, 53-62.
4. Briggs, M. R.; Yokoyama, C.; Wang, X.; Brown, M. S.; Goldstein, J. L. Nuclear protein that binds sterol regulatory element of lowdensity lipoprotein receptor promoter. J. Biol. Chem, 1993, 268, 14490-14496.
5. Hua, X.; Yokoyama, C.; Wu, J.; Briggs, R.; Brown, M. S.; Goldstein, J. L.; Wang, X. SREBP-2, a second basic-helix-loophelix-leu-cine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl. Acad. Sci. 1993, 90, 11603-11607
6. Goldstein, J. L.; Dana, S. E.; Faust, J. R.; Beaudet, A. L.; Brown, M. S. Role of lysosomal acid lipase in the metabolism of plasmalow-density lipoprotein. J. Biol. Chem., 1975, 250, 8487-8495.
7. Hoeg, J.M.; Demosky, S.J. Jr.; Pescovitz, O.H.; Brewer, H.B. Jr. Cholesteryl ester storage disease and Wolman's disease: Phenotypic variants of lysosomal acid cholesteryl ester hydrolase deficiency. Am. J. Hum. Genet., 1984, 36, 1190-1203
8. Rosenbaum, A.I.; Cosner, C.C.; Mariani, C. J.;Maxfield, F.R.; Wiest, O.;Helquist, P. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. J. Med. Chem., 2010, 22, 53(14), 5281-5289.
9. Azam, S.S.; Abbasi, S.W.; Batool, M. Structure modeling and docking study of HCV NS5B-3a RNA polymerase for the identification of potent inhibitors. Med. Chem. Res., 2013, 23(2), 618-627.
10. Azam, S.S.; Uddin, R.; Adan, A.S.; Haq, Z. Molecular docking studies of potent inhibitors of tyrosinase and a-glucosidase. Med. Chem. Res., 2012, 21(8), 1677-1683.
11. Roberts, N.A.; Martin, J.A.; Kinchington, D.; Broadhurst, A.V.; Craig, J.C. Rational design of peptide-based HIV proteinase inhibitors. J.C. Craig, Sci., 1990, 248, 358-361.
12. Blundell, T.; Sibanda, B.L.;Pearl, L. Three-dimensional structure, specificity and catalytic mechanism of renin. Nature, 1983, 304, 273-275
13. Joseph, N. Development of Neuraminidase Inhibitors as Anti-Influenza Virus Drugs. Drug Develop. Res., 1999, 46, 176-196.
14. Russell, R.J.; Haire, L.F.; Stevens, D.J.; Collins, P.J.; Lin, Y.P. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature, 2006, 443, 45-49
15. Von Itzstein, M.; Wu, W.Y.; Kok, G.B.; Pegg, M.S.; Dyason, J.C. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 1993, 363, 418-423
16. DesJarlais, R.L.; Seibel, G.L.; Kuntz, I.D.; Furth, P.S.; Alvarez, J.C. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Natl. Acad. Sci., 1990, 87, 6644-6648.
17. Fernandez, A.; Sanguino, A.; Peng, Z.;Crespo, A.; Ozturk, E. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. Cancer Res., 2007, 67, 4028-4033
18. Gangjee, A.; Jain, H.D.; Kurup, S. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II. Anticancer Agents. Med. Chem., 2008, 8, 205-231
19. Ghosh, A.K.; Gemma, S.; Takayama, J.; Baldridge, A.; Leshchenko-Yashchuk, S. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structurebased design, synthesis, biological evaluation and protein-ligand Xray studies.Org. Biomol. Chem., 2008, 6, 3703-3713.
20. Vaseeharan, B.; Valli, S.J. Insilico homology modeling of prophenoloxidase activating factor serine proteinase gene from the haemocytes of Fenneropenaeus indicus. J. Proteomics. Bioinform., 2011, 4, 53-57.
21. Roussel, A.; Miled, N.; Berti-Dupuis, L.; Riviere, M.; Spinelli, S.; Berna, P.; Gruber, V.; Verger, R.; Cambillau, C. Crystal structure of the open form of dog gastric lipase in complex with a phosphonate inhibitor. J. Biol. Chem., 2002, 277, 2266-2274
22. Šali, A.; Potterton, L.; Yuan, F.; van Vlijmen, H.; Karplus, M. Evaluation of comparative protein modeling by MODELLER. Proteins: Struct. Funct. Bioinf., 2004, 23, 318-326.
23. Laskowski, R.A.; MacArthur, M.W.; Moss, D.S.; Thornton, J.M. PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Cryst., 1993, 26, 283-291.
24. Eisenberg, D.; Lüthy, R.; Bowie, J.U. VERIFY3D: Assessment of protein models with three-dimensional profiles. Methods Enzymol., 1997, 277,396-404.
25. Colovos, C.; Yeates, T. O.; Verification of protein structures: patterns of nonbonded atomic interactions. Protein Science, 1993, 2(9), 1511-1519
26. Wiederstein, M.; Sippl, M.J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res., 2007, 35, W407-W410.
27. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera -a visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25, 1605-1612.
28. Andreas, W.G.; Mark, J. W.; Dong, Xu.; Duncan, P.; Scott, L. G.; Ross, C. W. Routine microsecond molecular dynamics simulations with AMBER -Part I: Generalized Born. J. Chem. Theory Comput., 2012, 8(5), pp 1542-1555.
29. Irwin, J.J.; Shoichet, B.K. ZINC -A free database of commercially available compounds for virtual screening. J.Chem. Inf. Model., 2005, 45, 177-182
30. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26
31. Sala, E.; Guasch, L.; Iwaszkiewicz, J.; Mulero, M.; Salvadó M.J. Identification of Human IKK-2 Inhibitors of Natural Origin (Part I): Modeling of the IKK-2 Kinase Domain, Virtual Screening and Activity Assays. PLoS ONE., 2011, 6(2), e16903.
32. Wishart, D.S.; Knox, C.; Guo, A.C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, DrugBank: A comprehensive resource for in silico drug discovery and exploration. J. Nucleic Acids Res, 2006, 34, D668-D672.
33. Rosenbaum, A.I.; Rujoi, M.; Huang, A.Y.; Du, H.; Grabowski, G.A. Maxfield for chemical screen to reduce sterol accumulation in niemann-pick c disease cells identifies novel lysosomal acid lipase inhibitors. Biochim. Biophys. Acta., 2009, 1791, 1155-1165.
34. Chioua, S.Y.; Yub, G.Y.; Lin, G. QSAR for inhibition of pseudomonas species lipase by 1-Acyloxy-3-N-n-octylcarbamylbenzenes. QSAR Comb. Sci., 2009, 3, 267-273.
35. Lin, G.; Tsaib, H.J.; Tsaia, Y.H. Cage Amines as the Stopper Inhibitors of Cholinesterases. Bioorg. Med. Chem. Lett., 2003, 13, 2887-2890
36. Goodsell, D.S.; Olson, A.J. Automated docking of substrates to proteins by simulated annealing. Proteins, 1990, 8, 195-202
37. Morris, G.M.; Goodsell, D.S.; Huey, R.; Olson, A.J. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput. Aided Mol. Des., 1996, 10, 293-304
38. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W. E.; Belew, R.K.; Olson, A.J. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-1662
39. Trott, O.; Olson, A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comp. Chem., 2010, 31, 455-461
40. Baxter, J. Local optima avoidance in depot location. J. Oper. Res. Soc., 1981, 32, 815-819
41. Blum, C.; Blesa, M.J.; Roli, A.; Sampels, M. Hybrid Metaheuristics: An Emerging Approach to Optimization. Springer-Verlag., 2008, Vol. 114.
42. Azam, S.S.; Saroosh, A.; Zaman, N.; Raza, S. Role of Nacetylserotonin O-methyltransferase in bipolar disorders and its dynamics. J. Mol. Liq., 2013, 185, 25-32.
43. Muchmore, S. W.; Souers, A. J.; Akritopoulou-Zanze, I. The Use of Three-Dimensional Shape and Electrostatic Similarity Searching in the Identification of a Melanin-Concentrating Hormone Receptor 1 Antagonist. Chem. Biol Drug Des., 2006, 67(2), 174-176
44. Molecular Operating Environment (MOE), 2012.10; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suit#910, Montreal, QC, Canada, H3A2R7, 2012, 10.
45. Panigrahi, S.K. Strong and weak hydrogen bonds in protein-ligand complexes of kinases: A comparative study. Amino Acids, 2008, 34, 617-633.
46. Patil, R.; Das, S.; Stanley, A.; Yadav, L.; Sudhakar, A. Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing. PLoS One. 2010 5, e12029.
47. Filippatos, T.D.; Derdemezis, C.S.; Gazi, I.F.; Nakou, E.S.; Mikhailidis, D.P.; Elisaf, M.S. Orlistat-associated adverse effects and drug interactions: A critical review. Drug Saf., 2008, 31, 53-65.
48. Roche Pharmaceuticals (July 2008). "Xenical". Roche Retrieved 2007-02-19 Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between October -December 2008". U.S. Food and Drug Administration. 4 June 2009. Retrieved 2009-06-08.